On March 21, 2012 Addex Pharmaceuticals (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, reported that it has changed its name to Addex Therapeutics (Press release, Addex Therapeutics, MAR 21, 2012, View Source;cHash=0fa4be2499463f7ab80ff5371e18b249 [SID:1234513477]). The name change reflects more closely the company’s focus on oral small molecule-based therapeutics. Addex’s ticker symbol on the Swiss Stock Exchange remains unchanged at ADXN.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Alongside the name change, Addex has revealed a new logo and website. The icon in the logo represents two things: the letter "X" from the Addex name and a receptor bound by a natural ligand or cell signaling molecule in the active site, depicted in blue, and an allosteric modulator bound to an allosteric site, in orange.
Addex has also introduced a new tag line: "expanding the realm of possible…" which is literally what the allosteric approach is doing for drug discovery. When applied to drug discovery, allostery offers the unique possibility of developing oral small molecule drugs for targets that were previously considered "undruggable" with conventional drug discovery approaches. Addex technology, therefore, expands the realm of druggable targets.
The new website provides information on the company’s strategy, pipeline and the allosteric modulation-based drug discovery and development technology platform. The new website also provides helpful information on the stock, corporate governance and corporate calendar featuring the company’s investor, media and scientific outreach activities.
This name change is subject to shareholder approval.